Edesa Biotech, Inc. (EDSA) Key Metrics
EDSA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $34.7M
- Enterprise value
- $37.6M
- P/E (TTM)
- —
- Forward P/E
- 0.2
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 96.9 10-yr median 1.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.22
EDSA key metrics, FY2016–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsEDSA valuation Price multiples at each fiscal year-end price.
Price / book−84.3%
1.1
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow yield−17.9 pts
−52.2%
FY2025 · hover or tap a bar for each year
FY2016FY2025
EDSA returns How much profit the business earns on the capital it uses.
Return on equity+37.1 pts
−99.6%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Return on invested capital−72.8 pts
−476.5%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Return on assets+14.3 pts
−82.9%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Asset turnover
0.00
FY2025 · hover or tap a bar for each year
FY2016FY2025
EDSA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
FY2025 · hover or tap a bar for each year
FY2016FY2025
Earnings per share
−$1.27
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow per share
−$1.29
FY2025 · hover or tap a bar for each year
FY2016FY2025
Book value per share+254.0%
$2.19
FY2025 · hover or tap a bar for each year
FY2016FY2025
Shares outstanding+77.5%
5.7M
FY2025 · hover or tap a bar for each year
FY2016FY2025
EDSA financial health Debt, liquidity and how easily interest is covered.
Net debt−$9.8M
−$10.8M
FY2025 · hover or tap a bar for each year
FY2016FY2025
Current ratio+1,067.6%
10.67
FY2025 · hover or tap a bar for each year
FY2016FY2025
EDSA efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+932 days
4,424 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
EDSA valuation history
Fiscal year-endToday10-year median
EDSA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EDSA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EDSA price vs earnings per share
Share price at year-endEPS (right axis)
EDSA key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $14.0M | $14.2M | $12.6M | — | — | — | — | — | — | — |
| Enterprise value | $3.2M | $13.2M | $7.3M | — | — | — | — | — | — | — |
| Price / book | 1.1 | 7.2 | 1.8 | — | — | — | — | — | — | — |
| Earnings yield | −51.2% | −43.4% | −66.4% | — | — | — | — | — | — | — |
| Free cash flow yield | −52.2% | −34.4% | −52.6% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.47 | $4.45 | $4.41 | $6.44 | $51.66 | $56.49 | $43.61 | $58.38 | $332.22 | $705.60 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Earnings per share | −$1.27 | −$1.93 | −$2.93 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.29 | −$1.53 | −$2.32 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.29 | −$1.53 | −$2.32 | — | — | — | — | — | — | — |
| Cash per share | $1.90 | $0.32 | $1.88 | — | — | — | — | — | — | — |
| Book value per share | $2.19 | $0.62 | $2.47 | — | — | — | — | — | — | — |
| Tangible book value per share | $1.85 | −$0.03 | $1.70 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| Debt per share | — | $0.01 | $0.03 | — | — | — | — | — | — | — |
| Shares outstanding | 5.7M | 3.2M | 2.9M | — | — | — | — | — | — | — |
| Change in shares outstanding | +77.5% | +11.8% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −99.6% | −136.7% | −101.9% | −156.3% | −120.4% | −88.6% | −32.9% | −53.9% | −51.0% | −49.5% |
| Return on invested capital (ROIC) | −476.5% | −403.7% | −355.3% | −380.0% | −507.2% | −442.8% | −370.2% | −441.6% | −473.8% | — |
| Return on assets (ROA) | −82.9% | −97.1% | −81.8% | −134.2% | −105.3% | −77.2% | −31.1% | −51.7% | −48.7% | −43.1% |
| Return on tangible assets | −62.2% | −355.6% | −124.8% | −188.8% | −109.3% | −76.9% | −47.6% | −42.8% | −65.2% | −38.8% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | −385.9% |
| Financial health | ||||||||||
| Total debt | — | $19,867 | $94,487 | $18,975 | $99,320 | $164,189 | — | — | — | — |
| Cash & short-term investments | $10.8M | $1.0M | $5.4M | $7.1M | $7.8M | $7.2M | $5.0M | $10.3M | $6.6M | $11.4M |
| Net debt | −$10.8M | −$1.0M | −$5.3M | −$7.1M | −$7.7M | −$7.0M | −$5.0M | −$10.3M | −$6.6M | −$11.4M |
| Debt / equity | — | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | — | — | — | — |
| Debt / assets | — | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | — | — | — | — |
| Current ratio | 10.67 | 0.91 | 3.53 | 4.25 | 8.29 | 5.30 | 12.23 | 21.60 | 21.06 | 19.40 |
| Quick ratio | 10.67 | 0.91 | 3.53 | 4.83 | 8.29 | 5.35 | 12.70 | 21.14 | 20.85 | 19.00 |
| Interest coverage | — | — | — | -22.3 | -202.5 | -67.4 | -49.8 | — | — | — |
| Working capital | $10.4M | −$157,205 | $4.6M | $7.0M | $10.6M | $6.6M | $5.2M | $10.2M | $6.4M | $11.5M |
| Invested capital | $1.7M | $963,702 | $1.8M | $2.3M | $5.3M | $2.1M | $225,547 | $983,038 | $833,706 | $908,462 |
| Tangible asset value | $10.5M | −$97,693 | $4.9M | $7.1M | $10.7M | $6.6M | $5.3M | $11.3M | $7.4M | $12.3M |
| Net current asset value | $10.4M | −$157,205 | $4.6M | $6.9M | $10.6M | $6.4M | $5.2M | $10.2M | $6.4M | $11.5M |
| Graham net-net per share | $1.80 | −$0.19 | $1.40 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | — | $0 | — | $0 |
| Capex / revenue | — | — | — | — | 1,229.2% | 10.4% | 2.0% | 180.7% | 132.6% | 31.6% |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.60 | 1.69 | 2.03 | 1.69 | 2.69 |
| Stock-based compensation / revenue | — | — | — | — | 639,093.8% | 182.0% | 11.3% | 72.8% | 50.6% | 20.4% |
| R&D / revenue | — | — | — | — | 3,589,414.4% | 1,012.6% | 266.9% | 985.3% | 864.4% | 136.0% |
| SG&A / revenue | — | — | — | — | 1,146,852.0% | 1,028.8% | 497.8% | 1,301.6% | 1,290.0% | 261.3% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | 1,237,449.6 | 169.0 | 114.8 | 36.6 | 69.6 | 34.9 |
| Days of inventory on hand | — | — | — | -3,877.2 | — | -3,157.8 | 12.9 | 119.8 | 108.4 | 130.5 |
| Days payables outstanding | 4,424.3 | 3,492.2 | 3,848.5 | 5,407.1 | 4,363.2 | 19,542.6 | 1,654.1 | 333.7 | 322.6 | 126.4 |
| Cash conversion cycle (days) | — | — | — | — | 1,233,086.5 | -22,531.3 | -1,526.4 | -177.3 | -144.5 | 39.1 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.16 | 3.18 | 9.96 | 5.24 | 10.45 |
| Payables turnover | 0.08 | 0.10 | 0.09 | 0.07 | 0.08 | 0.02 | 0.22 | 1.09 | 1.13 | 2.89 |
| Inventory turnover | — | — | — | — | — | — | — | 3.05 | 3.37 | 2.80 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.02 | 0.02 | 0.11 |
| Average receivables | $456,887 | $448,726 | $940,997 | $2.3M | $1.7M | $152,274 | $129,174 | $21,266 | $43,550 | $121,705 |
| Average payables | $1.4M | $1.8M | $1.9M | $1.8M | $1.4M | $942,380 | $459,010 | $407,166 | $472,296 | $390,620 |
| Average inventory | — | — | — | −$1.3M | — | −$152,274 | $3,583 | $146,190 | $158,772 | $403,355 |
| Intangibles / total assets | 14.6% | 54.5% | 24.5% | 19.7% | 16.3% | 23.1% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from EDSA's annual financial statements (latest annual report filed December 12, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EDSA valuation and financial ratios
Edesa Biotech earned a return on equity of −99.6% and a return on invested capital of −476.5% in fiscal 2025.
See the EDSA income statement, the EDSA chart for price history, or the EDSA stock overview for the latest quote and news.
EDSA key metrics FAQ
What is Edesa Biotech's return on equity?
Edesa Biotech's return on equity (ROE) was −99.6% in fiscal 2025: net income of -$7.2 million on average shareholders' equity of $7.2 million.
What is Edesa Biotech's ROIC?
Edesa Biotech's return on invested capital was −476.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Edesa Biotech's free cash flow yield?
Edesa Biotech generated -$7.3 million of free cash flow in fiscal 2025, a free cash flow yield of −52.2% on its market value at year-end ($14.0 million).
What is Edesa Biotech's current ratio?
Edesa Biotech's current ratio was 10.67 at the end of fiscal 2025: current assets were 10.67 times current liabilities.